Is EVMN or TSHA more profitable?

Evommune's return on equity of 0.00% beat Taysha Gene Therapies' return on equity. Company Net Margins Return on Equity Return on Assets Evommune N/A N/A N/A Taysha Gene Therapies N/A -56.07% -40.16%

Which has preferable earnings & valuation, IMCR or EVMN?

Immunocore has higher revenue and earnings than Evommune. Immunocore is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunocore $400.02M 4.52 -$35.51M -$0.55 N/A Evommune $13M 31.71 -$68.87M -$9.50 N/A

Does the media prefer IMCR or EVMN?

In the previous week, Immunocore had 1 more articles in the media than Evommune. MarketBeat recorded 2 mentions for Immunocore and 1 mentions for Evommune. Immunocore's average media sentiment score of 0.00 equaled Evommune'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunocore 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Evommune 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to RXRX or EVMN?

In the previous week, Recursion Pharmaceuticals had 1 more articles in the media than Evommune. MarketBeat recorded 2 mentions for Recursion Pharmaceuticals and 1 mentions for Evommune. Recursion Pharmaceuticals' average media sentiment score of 0.92 beat Evommune's score of 0.00 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Recursion Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evommune 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is EVMN or GENB more profitable?

Company Net Margins Return on Equity Return on Assets Evommune N/A N/A N/A Generate Biomedicines N/A N/A N/A

Which has stronger earnings and valuation, ANAB or EVMN?

AnaptysBio has higher revenue and earnings than Evommune. AnaptysBio is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AnaptysBio $234.60M 6.64 -$13.23M -$1.08 N/A Evommune $13M 31.71 -$68.87M -$9.50 N/A

Is ANAB or EVMN more profitable?

Evommune has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%. Company Net Margins Return on Equity Return on Assets AnaptysBio -11.53% N/A -7.75% Evommune N/A N/A N/A

Does the media favor ANAB or EVMN?

In the previous week, AnaptysBio had 1 more articles in the media than Evommune. MarketBeat recorded 2 mentions for AnaptysBio and 1 mentions for Evommune. AnaptysBio's average media sentiment score of 0.37 beat Evommune's score of 0.00 indicating that AnaptysBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AnaptysBio 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Evommune 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Evommune (EVMN) Competitors

$11.44 -0.78 (-6.35%)

Closing price 07/22/2026 03:59 PM Eastern

Extended Trading

$11.58 +0.13 (+1.14%)

As of 07/22/2026 07:34 PM Eastern

Compare

EVMN vs. TSHA, IMCR, RXRX, GENB, and ANAB

Should you buy Evommune stock or one of its competitors? MarketBeat compares Evommune with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Evommune include Taysha Gene Therapies (TSHA), Immunocore (IMCR), Recursion Pharmaceuticals (RXRX), Generate Biomedicines (GENB), and AnaptysBio (ANAB). These companies are all part of the "pharmaceutical products" industry.

How does Evommune compare to Taysha Gene Therapies?

Evommune (NYSE:EVMN) and Taysha Gene Therapies (NASDAQ:TSHA) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

In the previous week, Evommune had 1 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 1 mentions for Evommune and 0 mentions for Taysha Gene Therapies. Evommune's average media sentiment score of 0.00 equaled Taysha Gene Therapies'average media sentiment score.

Company	Overall Sentiment
Evommune	Neutral
Taysha Gene Therapies	Neutral

Evommune has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evommune	$13M	31.71	-$68.87M	-$9.50	N/A
Taysha Gene Therapies	$9.77M	166.47	-$109M	-$0.38	N/A

Evommune's return on equity of 0.00% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evommune	N/A	N/A	N/A
Taysha Gene Therapies	N/A	-56.07%	-40.16%

Evommune presently has a consensus target price of $45.63, suggesting a potential upside of 298.68%. Taysha Gene Therapies has a consensus target price of $12.77, suggesting a potential upside of 125.60%. Given Evommune's higher possible upside, analysts clearly believe Evommune is more favorable than Taysha Gene Therapies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evommune	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00

77.7% of Taysha Gene Therapies shares are held by institutional investors. 31.1% of Evommune shares are held by insiders. Comparatively, 3.5% of Taysha Gene Therapies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Evommune beats Taysha Gene Therapies on 8 of the 13 factors compared between the two stocks.

How does Evommune compare to Immunocore?

Immunocore (NASDAQ:IMCR) and Evommune (NYSE:EVMN) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and dividends.

Evommune has a net margin of 0.00% compared to Immunocore's net margin of -6.68%. Evommune's return on equity of 0.00% beat Immunocore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-6.68%	-7.07%	-2.55%
Evommune	N/A	N/A	N/A

84.5% of Immunocore shares are held by institutional investors. 10.1% of Immunocore shares are held by company insiders. Comparatively, 31.1% of Evommune shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Immunocore had 1 more articles in the media than Evommune. MarketBeat recorded 2 mentions for Immunocore and 1 mentions for Evommune. Immunocore's average media sentiment score of 0.00 equaled Evommune'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunocore	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Evommune	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immunocore presently has a consensus target price of $56.71, indicating a potential upside of 59.58%. Evommune has a consensus target price of $45.63, indicating a potential upside of 298.68%. Given Evommune's stronger consensus rating and higher probable upside, analysts plainly believe Evommune is more favorable than Immunocore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.40
Evommune	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79

Immunocore has higher revenue and earnings than Evommune. Immunocore is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$400.02M	4.52	-$35.51M	-$0.55	N/A
Evommune	$13M	31.71	-$68.87M	-$9.50	N/A

Summary

Evommune beats Immunocore on 10 of the 15 factors compared between the two stocks.

How does Evommune compare to Recursion Pharmaceuticals?

Recursion Pharmaceuticals (NASDAQ:RXRX) and Evommune (NYSE:EVMN) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

Recursion Pharmaceuticals currently has a consensus price target of $8.10, indicating a potential upside of 171.81%. Evommune has a consensus price target of $45.63, indicating a potential upside of 298.68%. Given Evommune's stronger consensus rating and higher possible upside, analysts clearly believe Evommune is more favorable than Recursion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Evommune	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79

89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 6.7% of Recursion Pharmaceuticals shares are held by insiders. Comparatively, 31.1% of Evommune shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Recursion Pharmaceuticals had 1 more articles in the media than Evommune. MarketBeat recorded 2 mentions for Recursion Pharmaceuticals and 1 mentions for Evommune. Recursion Pharmaceuticals' average media sentiment score of 0.92 beat Evommune's score of 0.00 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evommune	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Evommune has lower revenue, but higher earnings than Recursion Pharmaceuticals. Recursion Pharmaceuticals is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$74.68M	21.15	-$644.76M	-$1.20	N/A
Evommune	$13M	31.71	-$68.87M	-$9.50	N/A

Evommune has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -842.95%. Evommune's return on equity of 0.00% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%
Evommune	N/A	N/A	N/A

Summary

Evommune beats Recursion Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Evommune compare to Generate Biomedicines?

Evommune (NYSE:EVMN) and Generate Biomedicines (NASDAQ:GENB) are both small-cap manufacturing companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

In the previous week, Evommune had 1 more articles in the media than Generate Biomedicines. MarketBeat recorded 1 mentions for Evommune and 0 mentions for Generate Biomedicines. Evommune's average media sentiment score of 0.00 equaled Generate Biomedicines'average media sentiment score.

Company	Overall Sentiment
Evommune	Neutral
Generate Biomedicines	Neutral

Evommune presently has a consensus target price of $45.63, indicating a potential upside of 298.68%. Generate Biomedicines has a consensus target price of $25.40, indicating a potential upside of 82.73%. Given Evommune's higher probable upside, equities research analysts plainly believe Evommune is more favorable than Generate Biomedicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evommune	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Company	Net Margins	Return on Equity	Return on Assets
Evommune	N/A	N/A	N/A
Generate Biomedicines	N/A	N/A	N/A

Evommune has higher earnings, but lower revenue than Generate Biomedicines. Generate Biomedicines is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evommune	$13M	31.71	-$68.87M	-$9.50	N/A
Generate Biomedicines	$30.30M	58.81	-$137.17M	-$1.07	N/A

Summary

Evommune beats Generate Biomedicines on 6 of the 10 factors compared between the two stocks.

How does Evommune compare to AnaptysBio?

AnaptysBio (NASDAQ:ANAB) and Evommune (NYSE:EVMN) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

In the previous week, AnaptysBio had 1 more articles in the media than Evommune. MarketBeat recorded 2 mentions for AnaptysBio and 1 mentions for Evommune. AnaptysBio's average media sentiment score of 0.37 beat Evommune's score of 0.00 indicating that AnaptysBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AnaptysBio	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Evommune	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

AnaptysBio currently has a consensus target price of $81.82, suggesting a potential upside of 55.52%. Evommune has a consensus target price of $45.63, suggesting a potential upside of 298.68%. Given Evommune's stronger consensus rating and higher possible upside, analysts plainly believe Evommune is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AnaptysBio	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Evommune	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79

Evommune has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%.

Company	Net Margins	Return on Equity	Return on Assets
AnaptysBio	-11.53%	N/A	-7.75%
Evommune	N/A	N/A	N/A

AnaptysBio has higher revenue and earnings than Evommune. AnaptysBio is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AnaptysBio	$234.60M	6.64	-$13.23M	-$1.08	N/A
Evommune	$13M	31.71	-$68.87M	-$9.50	N/A

Summary

Evommune beats AnaptysBio on 7 of the 13 factors compared between the two stocks.

Get Evommune News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EVMN vs. The Competition

Export

Metric	Evommune	Industry	Manufacturing Sector	NYSE Exchange
Market Cap	$440.14M	$3.13B	$8.16B	$23.48B
Dividend Yield	N/A	15.22%	38.39%	4.18%
P/E Ratio	-1.20	13.18	23.59	30.84
Price / Sales	31.71	2,742.70	134.93	20.80
Price / Cash	N/A	25.80	165.13	32.60
Price / Book	1.76	8.67	13.19	4.75
Net Income	-$68.87M	-$34.07M	$120.21M	$1.07B
7 Day Performance	-8.14%	-0.25%	-1.10%	-0.13%
1 Month Performance	-49.24%	-0.68%	-2.48%	1.46%
1 Year Performance	N/A	11.50%	10.49%	16.19%

Evommune Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EVMN Evommune	2.9878 of 5 stars	$11.44 -6.4%	$45.63 +298.7%	N/A	$440.14M	$13M	N/A	45
TSHA Taysha Gene Therapies	2.7596 of 5 stars	$5.97 -3.6%	$12.62 +111.3%	+115.2%	$1.78B	$9.77M	N/A	180	Analyst Forecast
IMCR Immunocore	2.7293 of 5 stars	$34.47 -0.6%	$56.71 +64.5%	-4.3%	$1.76B	$400.02M	N/A	320	Analyst Upgrade
RXRX Recursion Pharmaceuticals	3.4197 of 5 stars	$3.02 -8.8%	$8.10 +168.2%	-54.4%	$1.75B	$74.68M	N/A	400
GENB Generate Biomedicines	2.062 of 5 stars	$13.66 -2.9%	$25.40 +85.9%	N/A	$1.75B	$30.30M	N/A	312

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:EVMN) was last updated on 7/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evommune (EVMN) Competitors

EVMN vs. TSHA, IMCR, RXRX, GENB, and ANAB

How does Evommune compare to Taysha Gene Therapies?

Summary

How does Evommune compare to Immunocore?

Summary

How does Evommune compare to Recursion Pharmaceuticals?

Summary

How does Evommune compare to Generate Biomedicines?

Summary

How does Evommune compare to AnaptysBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVMN vs. The Competition

Evommune Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evommune (EVMN) Competitors

EVMN vs. TSHA, IMCR, RXRX, GENB, and ANAB

How does Evommune compare to Taysha Gene Therapies?

Does the media prefer EVMN or TSHA?

Which has preferable valuation & earnings, EVMN or TSHA?

Is EVMN or TSHA more profitable?

Do analysts prefer EVMN or TSHA?

Do institutionals and insiders believe in EVMN or TSHA?

Summary

How does Evommune compare to Immunocore?

Is IMCR or EVMN more profitable?

Do insiders & institutionals believe in IMCR or EVMN?

Does the media prefer IMCR or EVMN?

Do analysts prefer IMCR or EVMN?

Which has preferable earnings & valuation, IMCR or EVMN?

Summary

How does Evommune compare to Recursion Pharmaceuticals?

Do analysts rate RXRX or EVMN?

Do institutionals and insiders believe in RXRX or EVMN?

Does the media refer more to RXRX or EVMN?

Which has stronger earnings and valuation, RXRX or EVMN?

Is RXRX or EVMN more profitable?

Summary

How does Evommune compare to Generate Biomedicines?

Does the media prefer EVMN or GENB?

Do analysts recommend EVMN or GENB?

Is EVMN or GENB more profitable?

Which has higher valuation & earnings, EVMN or GENB?

Summary

How does Evommune compare to AnaptysBio?

Does the media favor ANAB or EVMN?

Do analysts rate ANAB or EVMN?

Is ANAB or EVMN more profitable?

Which has stronger earnings and valuation, ANAB or EVMN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVMN vs. The Competition

Evommune Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools